In this study estimations of in vivo and in vitro gentamicin susceptibility for a series of strains of Pseudomonas aeruginosa were compared. The series included an extremely susceptible strain, typically susceptible strains by current susceptibility criteria, and strains with enzymatic and permeability-mediated resistance. In vivo testing was done by using a mice protection test involving six 1-h doses of gentamicin and an inoculum of 50 50% lethal doses of P. aeruginosa. Both normal mice and cyclophosphamide-treated mice were used. It was found that peak serum levels and serum levels of gentamicin obtained just prior to the sixth dose (fifth dose trough levels) required for protection were much higher than miniimal inhibitory concentrations (MICs) or minimal bactericidal concentrations (MBCs) obtained in high-cation medium. However, first dose trough levels were similar to MICs or-MBCs. Only an extremely susceptible strain, 280, could be treated at antibiotic dosages and serum levels which are considered likely to be safe in humans. A distinct inoculum effect was found in the mice tests, with a 10-fold increase in inoculum producing a 4-fold increase in the amount of gentamicin required, but no inoculum effect was found for MICs. These results suggest that current susceptibility criteria in use for gentamicin and P. aeruginosa overestimate gentamicin susceptibility, particularly when low-cation growth medium is used for susceptibility testing and when treating disseminated infection.
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Gentamicin, either alone or in combination with carbenicillin, is currently considered to be one of the most useful antibiotics for treatment of infection by Pseudomonas aeruginosa. Despite many years of clinical experience, there is still considerable doubt about the efficacy of gentamicin in the treatment of Pseudomonas sepsis. Poor survival rates reported in several studies ofPseudomonas bacteremia suggest that gentamicin is not highly effective in disseminated infections (8, 14, 16 ), yet most strains of P. aeruginosa are considered susceptible by current laboratory in vitro susceptibility testing results.
In the present study we examined the relationship of gentamicin susceptibility to in vivo efficacy of gentamicin in mouse models of disseminated infection by using a series of isogenic P. aeruginosa strains with different R-factors and a nonisogenic series varying in gentamicin susceptibility and virulence. Currently if strains have miniimal inhibitory concentrations (MICs) of -6 they are regarded as susceptible (17) . We have included infection of cyclophosphamidetreated mice as a model of infection of hosts with compromised host defenses. Because the apparent susceptibility of P. aeruginosa to aminoglycosides is very highly influenced by media conditions (9, 10, 20, Table 2 ). Minimal medium used was a low-phosphate, tris(hydroxymethyl)aminomethane-buffered medium previously described (4 Mouse protection tests. Mice were injected i.p. with 50 LD50 of the strain in question and treated by subcutaneous injections of serial twofold dilutions of gentamicin, covering the range of 2.5 to 80 mg/kg, beginning 1 h after infection. Deaths were counted at 48 h and the results were analyzed by the SpearmanKarber method (7) . Each 50% protective dose (PD50) determination used 30 mice with 5 mice at each dose level. PD50 determinations were repeated three or more times, and the data pooled for the PD5o were reported. Reproducibility between repetitions was within a factor of 100°2. The virulence of the inoculum was checked with each test by inoculating groups of mice with 50 LD50 and 0.5 LD50. Experiments were discarded in which inocula of 50 LD50 were not uniformly lethal or inocula of 0.5 LD50 caused deaths. Bacteria were recovered from the heart tissue of animals dying from infection and were used to confirm the identity of the infecting strain (Table 1) .
Serum gentamicin levels. Serum levels of gentamicin were determined by a radioenzymatic assay based on that described by Haas and Davies (12) modified by the use of the gentamicin 3-N-acetyl transferase from Escherichia coli JR89. Serum levels were measured at 5 or 10 min after gentamicin injection for peak serum levels and at 5-to 10-min intervals thereafter for up to Table 4 ).
Susceptibility testing in low-cation media gave MICs which were significantly lower than in high-cation medium (Table 2) .
Virulence tests. Table 3 gives LD50 values for the various strains of P. aeruginosa when given i.p. to normal and cyclophosphamidetreated mice. These studies were used to standardize the bacterial inoculum in an animal model of P. aeruginosa infection of normal hosts as well as hosts with impaired defense mechanisms. The strains as shown in Table 3 varied in virulence as judged by LD50. Strain PA103 is exceptionally virulent and has been recommended as a reference strain for mouse protection tests (6) . The presence of R-factor R130 and RUA7 did not significantly affect the virulence of strain 280 in mice. These strains thus provide a set of strains of nearly identical virulence but varying in MIC of gentamicin over the range of clinical susceptibility. R-factor R151 enhanced virulence of strain 280, although it did not alter the virulence of another P. aeruginosa strain, ML4262.
Cyclophosphamide-treated mice were clearly more susceptible to infection with all strains tested ( Table 3) . These mice represent a model of infection with P. aeruginosa in which host defense has been compromised. Such circumstances are common in human infections with P. (2) .
In cyclophosphamide-treated mice the PD50 values were lower in all cases where successful therapy was possible. This illustrates the role of inoculum on the level of gentamicin required for animal protection. If the inoculum was raised for these mice by 10-fold, the PD50 was significantly increased (Table 5 ). This is consistent with the inoculum effect described by Davis (5 (7) .
were necessary to achieve 50% protection, and no protection was achieved with strain 280(R130).
In all of these studies only strain 280 could be treated with doses of gentamicin which would be considered nontoxic on a weight basis in humans (11) . In addition, peak serum levels required to protect 50% of normal or cyclophosphamide-treated mice from strain 280 would be in the high therapeutic range reported for human infections. The remainder of dosages resulted in very high serum levels and significant accumulation in trough levels.
Heart blood from moribund mice was collected, diluted in MHB, grown to an absorbance at 600 nm reading of 0.5, and used as an inoculum for determination of MIC. No change in MIC was found for any strain as the result of animal passage.
Minimal bactericidal levels were performed on strains 280 and PA103 in MHB, in MHB and pooled mouse serum (from uninoculated mice) in equal parts, and in mouse serum. MBCs were 0.5 and 4 ,ug/ml, respectively, and were the same in each testing condition. Thus gentamicin had identical antibacterial efficacy in broth as in 50 or 100% serum.
DISCUSSION
The normal mouse system used in this study resembles severe disseminated infection with P. aeruginosa in humans. The results from the cyclophosphamide-treated mouse model parallel the increase in susceptibility to P. aeruginosa seen in patients with complex impairment of host defenses, for example with immunosuppression, various leukemias, burns, and advanced malignancies. We feel that it is in circumstances of disseminated infection that effective antibiotic therapy is most needed. In turn it seems essential that susceptibility testing of P. aeruginosa be as dependable as possible for such situations so that not only will the most effective drug(s) be selected for therapy but appropriate dosages will be given. With the exception of strain 280, all of the strains in this study identifled as susceptible by ordinary susceptibility testing criteria required very high dosages of gentamicin to produce 50% protection in normal or cyclophosphamide-treated mice. Even strain 280 required large doses on a weight basis. In summary, none of the strains tested, with the possible exception of strain 280, acted as gentamicin-susceptible strains. All strains tested except strain 280 would be better regarded as resistant.
Strain 280 and its R+ derivatives of equal virulence show that an increase in MIC is associated with a reduction in susceptibility, as would be expected. All strains illustrate that peak serum levels must exceed MICs by severalfold before 50% protective dose levels are achieved. Similarly, peak serum levels exceeded MBCs by 1.5-to 14-fold. The association between first dose trough levels and MICs was closer. First dose trough levels associated with 50% protection were 0.5 to 3 times MICs and 0.25 to 1.5 times MBCs. Thus, a correlation with trough levels seems to be a more reliable way to predict therapeutic efficacy. Unfortunately this is not the current approach, as MICs are most frequently correlated with peak serum levels. It is equally unfortunate that most of the first dose trough levels required to achieve 50% protection with our strains and models would be considered toxic in humans. Current investigations have shown that trough levels greater than 4 jig/ml are more likely to be associated with toxicity in humans (11) . Fifth dose trough levels would be of even greater concern based on such toxicity criteria, even with strain 280. Thus, whatever the criteria selected, the strains examined in this study with the possible exception of strain 280 cannot be regarded as susceptible to gentamicin if potential toxicity is to be considered, as it must be with gentamicin.
Considerable caution is necessary in forming conclusions on human P. aeruginosa infections based on results from animal models. However, despite reservations, animal models clearly take into account many factors that in vitro susceptibility methods do not, and are likely to be a much better test of susceptibility.
From our results we conclude that current criteria for susceptibility based on designation of strains with MICs of gentamicin s6,ug/ml as susceptible overestimate the susceptibility of P. aeruginosa for disseminated infections. This conclusion holds even with the use of media containing calcium and magnesium at levels similar to those of human serum. Susceptibility testing with a medium containing a low concentration of these cations grossly overestimates susceptibility. These conclusions are supported by the results of many human cases studies (8, 14, 16, 21) . Other studies using animals also 800 NICAS AND BRYAN on November 1, 2017 by guest http://aac.asm.org/ Downloaded from support our conclusions in that many strains of P. aeruginosa apparently susceptible by in vitro criteria to gentamicin do not respond satisfactorily unless large gentamicin doses are used (1, 5, 13, 15, 24, 25) . Our results also demonstrate that MICs are not a satisfactory guide to the peak serum levels needed to insure therapeutic success with P. aeruginosa in disseminated infection except that serum levels must exceed MICs by severalfold. In addition, we feel the development of susceptibility criteria based on peak serum levels is unsatisfactory; susceptibility criteria correlating MICs and trough levels have more predictive value. The marked effect of the size of inoculum on the PD50 of gentamicin suggests that intensive treatment of disseminated P. aeruginosa infections should be started early when smaller numbers of P. aeruginosa are present.
A point of concern is that the present gentamicin susceptibility criteria as applied to P. aeruginosa isolates from severe infection may encourage underdosing with gentamicin, particularly if peak serum levels are used to guide therapy. This concern is based on current gentamicin dosages in frequent use and drug levels usually obtained. We feel this is a major reason to reexamine susceptibility criteria for P. aeruginosa to gentamicin.
